ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant progress on development of highly accurate antibody test for COVID-19
Incorporation of ProMIS proprietary peptide antigens in the next phase of development is anticipated to support determination of whether or not antibodies detected in the serology assay possess virus neutralizing activity.
- Incorporation of ProMIS proprietary peptide antigens in the next phase of development is anticipated to support determination of whether or not antibodies detected in the serology assay possess virus neutralizing activity.
- Starting next year, and throughout 2021 and beyond, we anticipate that billions of people will receive COVID-19 vaccines, stated ProMIS executive chairman, Eugene Williams.
- ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
- To learn more about COVID-19 antibody testing listen to the podcast, Saving Minds, at iTunes or Spotify .